Article

Prediction of individualized cardiac safe dose of doxorubicin through integration of hiPSC-cardiomyocytes based in vitro testing and QSP-PK-TD model

2024-01-31

Abstract excerpt

BACKGROUND AND PURPOSE The advanced human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CMs) technology provides a novel in vitro platform for identification of the patients at high risk of drug-induced cardiotoxicity. Purpose of the current study is to develop an in vitro to in vivo translational platform to predict the incidence of drug induced cardiac dysfunction in clinic with hiPSC-CMs based in v...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 213439fe-2d8d-593e-a1ce-dca4a69f0fa4
DOI: 10.22541/au.170670534.48993604/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prediction of individualized cardiac safe dose of doxorubicin through integration of hiPSC-cardiomyocytes based in vitro testing and QSP-PK-TD modelDOI 10.22541/au.170670534.48993604/v1Read

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity Read

Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessmentSemantic proximity Read

Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.Semantic proximity Read

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitorsSemantic proximity Read

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Semantic proximity Read

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity ScreeningSemantic proximity Read

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read

An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.Semantic proximity Read

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesSemantic proximity Read

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterizationSemantic proximity Read

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessmentSemantic proximity Read

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read